Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Alpharma has agreed to be acquired by King Pharmaceuticals in a stock deal valued at $1.6 billion. The agreement follows a series of offers by King that Alpharma CEO Dean J. Mitchell rejected, claiming they undervalued his company. In September, King took its bid directly to shareholders, upping the offer from $33 per share to $37. With 73% of shares tendered, Alpharma has now officially backed the deal. "The transformation of Alpharma over the past two years has created tremendous shareholder value, and we have consistently said we will act in the best interest of shareholders," Mitchell says.
This article has been sent to the following recipient: